Emerging evidence from the DESTINY-Lung01/02 trials suggests intracranial activity of HER2-directed ADC in HER2-mutant NSCLC.44 The intracranial efficacy of SHR-A1811 requires further research. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.